Biocon Ltd News Today

In return, to get committed access to 100 million vaccine doses annually for 15 years with commercialisation rights of the SILS vaccine portfolio.

Biocon shares were trading 0.45% up on BSE

Data indicates that the antibody could provide rapid and durable protection against Covid-19 for up to one year

The research projects would support national efforts in preparing for and responding to future pandemics.

But will ramp up production, says Chief Medical Officer Sandeep Athalye

Company faced pricing pressure in the US, travel restrictions delayed approvals & launch new products

Performance driven by biosimilars, research services and generics businesses

For the full year, revenues have grown 21 per cent to ₹2,800 crore

This is the first time that a biopharma company from India has been awarded an ISPE FOYA mention

She will serve for a term of three years

The drug is used in treatment of cancer as part of a specific regimen

Strong surge seen on open positions in the last few days